■ Participants from the 2011 and 2010 US National Health and Wellness Surveys (NHWS) completed an internet-based screening survey assessing use, misuse, and abuse of prescription opioid medications in the preceding 3 months ■ 225 respondents reported abuse of prescription opioid medication in the prior 3 months and provided usable data for healthcare use
MEASURES
■ All measures were by self-report ■ Abuse was defined as taking prescription opioid medication for the purpose of getting high ■ Tampering was defined as use of the medication in any form other than the original or taking in combination with alcohol ■ Healthcare resource utilization in prior 3 months, related and unrelated to opioid medication use
• Outpatient (non-emergency) visits
• ER visits
• Hospitalizations
• Days of drug rehabilitation ■ Comorbidities were summarized using the Charlson Comorbidity Index (CCI) calculated from self-report of diagnosed medical conditions [5] COST ESTIMATION ■ Direct (non-rehabilitation) healthcare costs
• Estimated by multiplying the frequency of each type of healthcare service by the 2011 median unit cost in the Truven Market Scan database for that service stratified by presence of an opioid abuse code (304.7x, 305.5x, 965.00, 965.02, 965 .09) (Table 1) • An alternative analysis substituted unit costs drawn from the 2011 Medical Expenditure Panel Survey (MEPS) stratified by age of the patient and type of service ( ■ Drug rehabilitation costs were estimated using mean unit costs from the Alcohol and Drug Services Study Cost Study, inflated to 2011 dollars using the medical services component of the US consumer price index (Table 3 ) 
STATISTICAL ANALYSIS
■ T-tests were used to compare those who tampered and those who did not tamper on continuous variables ■ Chi-square tests were used to compare the two groups on categorical variables ■ Generalized linear models (GLMs) were used to quantify the direct medical costs using negative binomial distribution and log-link function
• Covariates included tampering, age, white race, sex, household income (≥$50k vs. lower/decline to answer), presence of a psychiatric condition, obesity (body mass index ≥30 kilograms/meter 2 ), self-reported alcoholism, exercise in prior month, possession of health insurance, use of an opioid reported in NHWS, current smoker, employment status, and CCI
RESULTS
■ Those who tampered were less likely to be white, to currently smoke cigarettes, be obese, report a psychiatric comorbidity or alcoholism, and were slightly younger than those who abused without tampering ( ■ Those who abused through tampering had significantly higher mean estimated healthcare costs than those who did not tamper during the 3-month recall period (Table 5) • Non-opioid-related medical visits were higher by $11,944 (p<0.001)
• Opioid-related medical visits were higher by $6,567 (p<0.001)
• Drug rehabilitation costs were higher by $303 (p<0.001)
• Total direct incremental cost was $18,814 (p<0.001) ■ Median total incremental costs were also higher by $3,803 for those who tampered ■ Conclusions were similar when MEPS unit costs were applied (Table 6) • Higher mean costs for non-opioid-related medical visits ($10,330, p<0.001)
• Higher mean costs for opioid-related medical visits ($10,684, p<0.001)
• Mean drug rehabilitation costs were significantly higher ($303, p<0.001)
• Total mean incremental cost was $21,317 (p<0.001) ■ Median total incremental costs were also higher by $5,928 for those who tampered ■ GLMs indicated higher total direct costs and opioid-specific direct costs associated with tampering after adjusting for confounders (both p<0.001; Figure 1) ■ The difference between costs depended on whether the costs considered were total or opioid-specific as well as the source of the unit costs, but costs were many times higher among those who tampered relative to those who did not 
CONCLUSIONS
■ Tampering with prescription opioid medications in order to get high is associated with significantly increased medical costs compared to those who abuse without tampering ■ The difference in costs associated with tampering remains significant after adjusting for differences in respondent characteristics ■ Efforts to reduce tampering, such as the use of abuse-deterrent formulations of prescription opioid medications, may provide net healthcare savings.
